Skip to main content
Top
Published in: Heart Failure Reviews 6/2019

01-11-2019 | Arterial Diseases

Cost-effectiveness of coronary artery bypass graft and percutaneous coronary intervention compared to medical therapy in patients with coronary artery disease: a systematic review

Authors: Saeed Sheikh Gholami, Farbod Ebadi Fard Azar, Aziz Rezapour, Masih Tajdini

Published in: Heart Failure Reviews | Issue 6/2019

Login to get access

Abstract

Coronary artery disease (CAD) has significant social and economic implications. It is necessary to create tools to identify the most cost-effectiveness treatments, which can assist clinicians in their therapeutic decisions so that the maximum possible benefit is reached with the lowest possible cost. Effectiveness must be measured by final treatment goals in which the most effective interventions are those with the lowest costs. This study is aimed to systematically review and compare the studies conducted on the cost-effectiveness of the three coronary artery disease treatment strategies (medical treatment, percutaneous coronary intervention, and coronary artery bypass graft). In this systematic review, the databases NHS Economic Evaluation Database, Embase, MEDLINE, Science Direct, and Scopus were searched for studies on the cost-effectiveness of coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) compared to medical therapy (MT) in patients with coronary artery disease between 1 January 2004 to 30 September 2018. The quality appraisal of the included studies was examined using the Consolidated Health Economics Evaluation Reporting Standards (CHEERS) statement. Out of 186 unique retrievals, 8 studies were included. The results showed that the all studies clearly stated the time horizon of the study and included direct medical costs in their analysis. In addition, in most of the studies, quality-adjusted life years (QALY) were the main outcome used for measuring the effectiveness. The studies reported various ranges of the incremental cost-effectiveness ratio (ICER); accordingly, the highest ratio was observed in the USA ($212,800) for PCI v MT and the lowest ratio was observed in Brazil ($4403) for CABG v MT. Although the results of the studies were different in terms of a number of aspects, such as the viewpoint of the study, the study horizons, and the costs of expenditure items, they reached similar results. Based on the result of the present study, it seems that each three treatment strategies for CAD yielded improvements in QALY.
Literature
1.
go back to reference Allender S, Scarborough P, Peto V, Rayner M (2014).European cardiovascular disease statistics 2012 European heart network: Brussels. Allender S, Scarborough P, Peto V, Rayner M (2014).European cardiovascular disease statistics 2012 European heart network: Brussels.
2.
go back to reference Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ et al (2013) Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 129(3):232 Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ et al (2013) Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 129(3):232
3.
go back to reference Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carrié D, Clayton TC, Danchin N, Flather M, Hamm CW, Hueb WA, Kähler J, Kelsey SF, King SB, Kosinski AS, Lopes N, McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ (2009) Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 373(9670):1190–1197CrossRef Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carrié D, Clayton TC, Danchin N, Flather M, Hamm CW, Hueb WA, Kähler J, Kelsey SF, King SB, Kosinski AS, Lopes N, McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ (2009) Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 373(9670):1190–1197CrossRef
4.
go back to reference Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB (2007) A randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 115(9):1082–1089CrossRef Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB (2007) A randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 115(9):1082–1089CrossRef
5.
go back to reference Sculpher MJ, Buxton MJ, Seed P, Pocock SJ, Henderson RA, Parker J, Joy MD, Sowton E, Hampton JR, for RITA trial participants (1994) Health service costs of coronary angioplasty and coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial. Lancet 344(8927):927–930CrossRef Sculpher MJ, Buxton MJ, Seed P, Pocock SJ, Henderson RA, Parker J, Joy MD, Sowton E, Hampton JR, for RITA trial participants (1994) Health service costs of coronary angioplasty and coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial. Lancet 344(8927):927–930CrossRef
6.
go back to reference Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJRM, Schönberger JPAM, Buller N, Bonser R, van den Brand M, van Herwerden L, Morel MA, van Hout B, Arterial Revascularization Therapies Study Group (2001) Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344(15):1117–1124CrossRef Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJRM, Schönberger JPAM, Buller N, Bonser R, van den Brand M, van Herwerden L, Morel MA, van Hout B, Arterial Revascularization Therapies Study Group (2001) Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344(15):1117–1124CrossRef
7.
go back to reference Rezapour A, Faradonbeh SB, Alipour V, Yusefvand M (2018) Effectiveness of revascularization interventions compared with medical therapy in patients with ischemic cardiomyopathy: a systematic review protocol. Medicine. 97(10):e9958CrossRef Rezapour A, Faradonbeh SB, Alipour V, Yusefvand M (2018) Effectiveness of revascularization interventions compared with medical therapy in patients with ischemic cardiomyopathy: a systematic review protocol. Medicine. 97(10):e9958CrossRef
8.
go back to reference Chaitman BR, Ryan TJ, Kronmal RA, Foster ED, Frommer PL, Killip T (1990) Coronary artery surgery study (CASS): comparability of 10 year survival in randomized and randomizable patients. J Am Coll Cardiol 16(5):1071–1078CrossRef Chaitman BR, Ryan TJ, Kronmal RA, Foster ED, Frommer PL, Killip T (1990) Coronary artery surgery study (CASS): comparability of 10 year survival in randomized and randomizable patients. J Am Coll Cardiol 16(5):1071–1078CrossRef
9.
go back to reference Weintraub WS, Becker ER, Mauldin PD, Culler S, Kosinski AS, King Iii SB (2000) Costs of revascularization over eight years in the randomized and eligible patients in the Emory Angioplasty Versus Surgery Trial (EAST). Am J Cardiol 86(7):747–752CrossRef Weintraub WS, Becker ER, Mauldin PD, Culler S, Kosinski AS, King Iii SB (2000) Costs of revascularization over eight years in the randomized and eligible patients in the Emory Angioplasty Versus Surgery Trial (EAST). Am J Cardiol 86(7):747–752CrossRef
10.
go back to reference Weintraub WS, Boden WE, Zhang Z, Kolm P, Zhang Z, Spertus JA, Hartigan P, Veledar E, Jurkovitz C, Bowen J, Maron DJ, O'Rourke R, Dada M, Teo KK, Goeree R, Barnett PG, Department of Veterans Affairs Cooperative Studies Program No. 424 (COURAGE Trial) Investigators and Study Coordinators (2008) Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients clinical perspective. Circulation: Cardiovascular Quality and Outcomes 1(1):12–20 Weintraub WS, Boden WE, Zhang Z, Kolm P, Zhang Z, Spertus JA, Hartigan P, Veledar E, Jurkovitz C, Bowen J, Maron DJ, O'Rourke R, Dada M, Teo KK, Goeree R, Barnett PG, Department of Veterans Affairs Cooperative Studies Program No. 424 (COURAGE Trial) Investigators and Study Coordinators (2008) Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients clinical perspective. Circulation: Cardiovascular Quality and Outcomes 1(1):12–20
11.
go back to reference Vieira RDO, Hueb W, Hlatky M, Favarato D, Rezende PC, Garzillo CL et al (2012) Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial. Circulation 126(11_suppl_1):S145–SS50CrossRef Vieira RDO, Hueb W, Hlatky M, Favarato D, Rezende PC, Garzillo CL et al (2012) Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial. Circulation 126(11_suppl_1):S145–SS50CrossRef
12.
go back to reference Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW (2015) Methods for the economic evaluation of health care programmes. 4ed. Oxford University Press: Oxford. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW (2015) Methods for the economic evaluation of health care programmes. 4ed. Oxford University Press: Oxford.
13.
go back to reference Almasiankia A, Kavosi Z, Keshtkaran A, Jafari A, Goodarzi S (2015) Equity in health care financing among Iranian households. Shiraz: SEMJ. 16(11–12):6 Almasiankia A, Kavosi Z, Keshtkaran A, Jafari A, Goodarzi S (2015) Equity in health care financing among Iranian households. Shiraz: SEMJ. 16(11–12):6
14.
go back to reference Ravangard R, Hatam N, Teimourizad A, Jafari A (2014) Factors affecting the technical efficiency of health systems: a case study of Economic Cooperation Organization (ECO) countries (2004–10). Int J Health Policy Manag 3(2):63–69CrossRef Ravangard R, Hatam N, Teimourizad A, Jafari A (2014) Factors affecting the technical efficiency of health systems: a case study of Economic Cooperation Organization (ECO) countries (2004–10). Int J Health Policy Manag 3(2):63–69CrossRef
15.
go back to reference Jafari A, Rezapour A, Hajahmadi M (2018) Cost-effectiveness of B-type natriuretic peptide-guided care in patients with heart failure: a systematic review. Heart Fail Rev 23(5):1–8CrossRef Jafari A, Rezapour A, Hajahmadi M (2018) Cost-effectiveness of B-type natriuretic peptide-guided care in patients with heart failure: a systematic review. Heart Fail Rev 23(5):1–8CrossRef
16.
go back to reference Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, on behalf of the CHEERS Task Force (2013) Consolidated health economic evaluation reporting standards (CHEERS) statement. Cost Effectiveness and Resource Allocation 11(1):6CrossRef Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, on behalf of the CHEERS Task Force (2013) Consolidated health economic evaluation reporting standards (CHEERS) statement. Cost Effectiveness and Resource Allocation 11(1):6CrossRef
17.
go back to reference Hlatky MA, Boothroyd DB, Melsop KA, Kennedy L, Rihal C, Rogers WJ, Venkitachalam L, Brooks MM, Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group (2009) Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Circulation 120(25):2550–2558CrossRef Hlatky MA, Boothroyd DB, Melsop KA, Kennedy L, Rihal C, Rogers WJ, Venkitachalam L, Brooks MM, Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group (2009) Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Circulation 120(25):2550–2558CrossRef
18.
go back to reference Griffin S, Barber J, Manca A, Sculpher M, Thompson S, Buxton M et al (2007) Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. BMJ 334(7594):624CrossRef Griffin S, Barber J, Manca A, Sculpher M, Thompson S, Buxton M et al (2007) Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. BMJ 334(7594):624CrossRef
19.
go back to reference Fidan D, Unal B, Critchley J, Capewell S (2007) Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000–2010. J Assoc Physicians 100(5):277–289 Fidan D, Unal B, Critchley J, Capewell S (2007) Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000–2010. J Assoc Physicians 100(5):277–289
20.
go back to reference Brandão SMG, Rezende PC, Brunner-La Rocca H-P, Ju YT, de Lima ACP, Takiuti ME et al (2018) Comparative cost-effectiveness of surgery, angioplasty, or medical therapy in patients with multivessel coronary artery disease: MASS II trial. CERA 16(1):55PubMed Brandão SMG, Rezende PC, Brunner-La Rocca H-P, Ju YT, de Lima ACP, Takiuti ME et al (2018) Comparative cost-effectiveness of surgery, angioplasty, or medical therapy in patients with multivessel coronary artery disease: MASS II trial. CERA 16(1):55PubMed
21.
go back to reference Caruba T, Katsahian S, Schramm C, Nelson AC, Durieux P, Bégué D et al (2014) Treatment for stable coronary artery disease: a network meta-analysis of cost-effectiveness studies. PLoS One 9(6):e98371CrossRef Caruba T, Katsahian S, Schramm C, Nelson AC, Durieux P, Bégué D et al (2014) Treatment for stable coronary artery disease: a network meta-analysis of cost-effectiveness studies. PLoS One 9(6):e98371CrossRef
22.
go back to reference Augustovski F, Iglesias C, Manca A, Drummond M, Rubinstein A, Martií SG (2009) Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region. Pharmacol Econ 27(11):919–929CrossRef Augustovski F, Iglesias C, Manca A, Drummond M, Rubinstein A, Martií SG (2009) Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region. Pharmacol Econ 27(11):919–929CrossRef
23.
go back to reference Baltussen RMPM, Hutubessy RCW, Evans DB, Murray CJM (2002) Uncertainty in cost-effectiveness analysis: probabilistic uncertainty analysis and stochastic league tables. Int J Technol Assess Healthc 18(1):112–119 Baltussen RMPM, Hutubessy RCW, Evans DB, Murray CJM (2002) Uncertainty in cost-effectiveness analysis: probabilistic uncertainty analysis and stochastic league tables. Int J Technol Assess Healthc 18(1):112–119
24.
go back to reference Ghabri S, Hamers FF, Josselin J-M, Harousseau J-L (2014) Exploring uncertainty in economic evaluation of medicines: a review of the first manufacturers’ submissions to the French National Authority for Health (HAS). Value Health 17(7):A441–A4A2CrossRef Ghabri S, Hamers FF, Josselin J-M, Harousseau J-L (2014) Exploring uncertainty in economic evaluation of medicines: a review of the first manufacturers’ submissions to the French National Authority for Health (HAS). Value Health 17(7):A441–A4A2CrossRef
25.
go back to reference Limwattananon S (2014) Sensitivity analysis for handling uncertainty in an economic evaluation. J Med Assoc Thail 97:S59–S64 Limwattananon S (2014) Sensitivity analysis for handling uncertainty in an economic evaluation. J Med Assoc Thail 97:S59–S64
26.
go back to reference Hatam N, Dehghani M, Habibian M, Jafari A (2015) Cost-utility analysis of IEV drug regimen versus ESHAP drug regimen for the patients with relapsed and refractoryh Hodgkin and non-Hodgkin’s lymphoma in Iran. Iran J Cancer Prev 8(5):e4061CrossRef Hatam N, Dehghani M, Habibian M, Jafari A (2015) Cost-utility analysis of IEV drug regimen versus ESHAP drug regimen for the patients with relapsed and refractoryh Hodgkin and non-Hodgkin’s lymphoma in Iran. Iran J Cancer Prev 8(5):e4061CrossRef
27.
go back to reference Claude J, Schindler C, Kuster GM, Schwenkglenks M, Szucs T, Buser P et al (2004) Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease: findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME). Eur Heart J 25(24):2195–2203CrossRef Claude J, Schindler C, Kuster GM, Schwenkglenks M, Szucs T, Buser P et al (2004) Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease: findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME). Eur Heart J 25(24):2195–2203CrossRef
28.
go back to reference Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS, COURAGE Trial Research Group (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356(15):1503–1516CrossRef Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS, COURAGE Trial Research Group (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356(15):1503–1516CrossRef
29.
go back to reference Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A (2010) Growing epidemic of coronary heart disease in low-and middle-income countries. Curr Probl Cardiol 35(2):72–115CrossRef Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A (2010) Growing epidemic of coronary heart disease in low-and middle-income countries. Curr Probl Cardiol 35(2):72–115CrossRef
Metadata
Title
Cost-effectiveness of coronary artery bypass graft and percutaneous coronary intervention compared to medical therapy in patients with coronary artery disease: a systematic review
Authors
Saeed Sheikh Gholami
Farbod Ebadi Fard Azar
Aziz Rezapour
Masih Tajdini
Publication date
01-11-2019
Publisher
Springer US
Published in
Heart Failure Reviews / Issue 6/2019
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-019-09811-3

Other articles of this Issue 6/2019

Heart Failure Reviews 6/2019 Go to the issue